What is HC Wainwright’s Forecast for ACAD FY2027 Earnings?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Stock analysts at HC Wainwright raised their FY2027 earnings estimates for shares of ACADIA Pharmaceuticals in a research report issued to clients and investors on Monday, May 19th. HC Wainwright analyst A. Fein now forecasts that the biopharmaceutical company will post earnings of $2.43 per share for the year, up from their prior estimate of $2.06. HC Wainwright has a “Buy” rating and a $32.00 price objective on the stock. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.70 per share. HC Wainwright also issued estimates for ACADIA Pharmaceuticals’ FY2028 earnings at $2.64 EPS and FY2029 earnings at $2.78 EPS.

A number of other analysts have also recently commented on the stock. BMO Capital Markets upped their target price on shares of ACADIA Pharmaceuticals from $24.00 to $28.00 and gave the company an “outperform” rating in a report on Monday. Mizuho upped their target price on shares of ACADIA Pharmaceuticals from $20.00 to $23.00 and gave the company a “neutral” rating in a report on Monday. Robert W. Baird upped their target price on shares of ACADIA Pharmaceuticals from $28.00 to $31.00 and gave the company an “outperform” rating in a report on Monday. Wall Street Zen raised shares of ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday. Finally, Needham & Company LLC upped their price target on ACADIA Pharmaceuticals from $27.00 to $30.00 and gave the stock a “buy” rating in a research report on Monday. Five investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat.com, ACADIA Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $26.83.

ACADIA Pharmaceuticals Stock Down 1.4%

ACADIA Pharmaceuticals stock opened at $21.55 on Wednesday. The business has a 50-day simple moving average of $16.29 and a two-hundred day simple moving average of $17.27. The company has a market cap of $3.61 billion, a P/E ratio of 27.63 and a beta of 0.47. ACADIA Pharmaceuticals has a 52-week low of $13.40 and a 52-week high of $25.23.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.10 by $0.01. The business had revenue of $244.32 million during the quarter, compared to the consensus estimate of $239.32 million. ACADIA Pharmaceuticals had a return on equity of 25.83% and a net margin of 13.83%. The business’s quarterly revenue was up 18.7% compared to the same quarter last year. During the same period in the previous year, the company posted $0.10 EPS.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Exchange Traded Concepts LLC bought a new stake in shares of ACADIA Pharmaceuticals during the first quarter valued at approximately $29,000. Picton Mahoney Asset Management purchased a new position in ACADIA Pharmaceuticals during the first quarter valued at $32,000. Banque Transatlantique SA bought a new stake in ACADIA Pharmaceuticals in the 1st quarter valued at $31,000. Virtus Fund Advisers LLC bought a new stake in ACADIA Pharmaceuticals in the 4th quarter valued at $39,000. Finally, Federated Hermes Inc. lifted its stake in ACADIA Pharmaceuticals by 231.5% in the 1st quarter. Federated Hermes Inc. now owns 2,317 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 1,618 shares in the last quarter. 96.71% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, EVP Mark C. Schneyer sold 3,498 shares of the business’s stock in a transaction dated Friday, May 2nd. The stock was sold at an average price of $14.60, for a total value of $51,070.80. Following the transaction, the executive vice president now directly owns 62,773 shares in the company, valued at $916,485.80. The trade was a 5.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Elizabeth A. Garofalo sold 4,919 shares of the company’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $18.23, for a total value of $89,673.37. Following the completion of the transaction, the director now directly owns 17,595 shares of the company’s stock, valued at approximately $320,756.85. This trade represents a 21.85% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 24,994 shares of company stock valued at $453,131. Company insiders own 26.50% of the company’s stock.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.